The Expression of MCM7 is a Useful Biomarker in the Early Diagnostic of Gastric Cancer

Yang, Jingyan; Li, Dong; Zhang, Yuan; Guan, Bingxin; Gao, Ping; Zhou, Xinming; Zhou, Chengjun

doi:10.1007/s12253-017-0251-1

Cited by 26 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 53 The potential application of MCM5 in identifying cell proliferation can be found in Merkel cell carcinoma 54 and malignant skin diseases. 55 Similar studies of MCM7 also have been reported in gastric cancer (GC), 56 esophageal lesions, 57 reactive mesothelial cells, and malignant cells. 58 , 59 Because of the close relationship between MCM gene and cell proliferation, MCM genes are also found to be associated with tumor progression.…”

Section: Discussionsupporting

confidence: 64%

Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy

Liao¹,

Han²,

Wang³

et al. 2018

CMAR

View full text Add to dashboard Cite

BackgroundThe aim of the current study was to investigate the potential prognostic value of minichromosome maintenance (MCM) genes in patients with early-stage pancreatic ductal adenocarcinoma (PDAC) after pancreaticoduodenectomy by using the RNA-sequencing dataset from The Cancer Genome Atlas (TCGA).MethodsAn RNA-sequencing dataset of 112 early-stage PDAC patients who received a pancreaticoduodenectomy was obtained from TCGA. Survival analysis was used to identify potential prognostic values of MCM genes in PDAC overall survival (OS).ResultsThrough mining public databases, we observed that MCM genes (MCM2, MCM3, MCM4, MCM5, MCM6, and MCM7) were upregulated in pancreatic cancer tumor tissue and have a strong positive coexpression with each other. Multivariate survival analysis indicated that a high expression of MCM4 significantly increased the risk of death in patients with PDAC, and time-dependent receiver operating characteristic analysis showed an area under the curve of 0.655, 0.587, and 0.509 for a 1-, 2-, and 3-year PDAC OS prediction, respectively. Comprehensive survival analysis of MCM4 using stratified and joint effects survival analysis suggests that MCM4 may be an independent prognostic indicator for PDAC OS. Gene set enrichment analysis indicated that MCM4 may participate in multiple biologic processes and pathways, including DNA replication, cell cycle, tumor protein p53, and Notch signaling pathways, thereby affecting prognosis of PDAC patients.ConclusionsOur study indicates that MCM2–7 were upregulated in pancreatic cancer tumor tissues, and mRNA expression of MCM4 may serve as an independent prognostic indicator for PDAC OS prediction after pancreaticoduodenectomy.

show abstract

Section: Discussionsupporting

confidence: 64%

Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy

Liao¹,

Han²,

Wang³

et al. 2018

CMAR

View full text Add to dashboard Cite

show abstract

“…The potential diagnostic value of MCM5 has also been investigated in genito-urinary tract cancer 11 , 43 , oesophageal cancer 12 , pancreaticobiliary malignancy 44 , 45 , and cervical cancer screening 41 . In addition, MCM7 can be used for the early diagnosis of gastric cancer 46 , and differential diagnosis between reactive mesothelial cells and malignant mesothelioma cells 47 , 48 . A study by Saydam et al reported that MCM2-7 genes were upregulated in meningiomas tumor tissues and could serve as potential diagnostic markers 49 .…”

Section: Discussionmentioning

confidence: 99%

Distinct Diagnostic and Prognostic Values of Minichromosome Maintenance Gene Expression in Patients with Hepatocellular Carcinoma

Liao¹,

Liu²,

Yang³

et al. 2018

J. Cancer

View full text Add to dashboard Cite

Background: The aim of the present study was to identify diagnostic and prognostic values of minichromosome maintenance (MCM) gene expression in patients with hepatocellular carcinoma (HCC).Methods: The biological function of the MCM genes were investigated by bioinformatics analysis. The diagnostic and prognostic values of the MCM genes were investigated by using the data of HCC patients from the GSE14520 and The Cancer Genome Atlas (TCGA) databases.Results: Bioinformatics analysis of the MCM genes substantiated that MCM2-7 genes were significantly enriched in DNA replication and cell cycle, and co-expressed with each other. These genes also co-expressed in HCC tumor tissue in both the GSE14520 and TCGA cohort. We also observed that the expression of the MCM2-7 genes was increased in tumor tissue, and diagnostic receiver operating characteristic analysis of MCM2-7 indicated that these genes could serve as sensitive diagnostic markers in HCC. Survival analysis in the GSE14520 cohort suggested that expression of MCM2, MCM4, MCM5, and MCM6 were significantly associated with hepatitis B virus-related HCC overall survival (OS). However, none of the MCM genes were associated with recurrence-free survival in the GSE14520 cohort. The validation cohort of TCGA suggested that the expression of MCM2, MCM6, and MCM7 were significantly correlated with HCC OS.Conclusion: Our study indicated that MCM2-7 genes may be potential diagnostic biomarkers in patients with HCC. Among them, MCM2 and MCM6 may serve as potential prognostic biomarkers for HCC.

show abstract

“…no. 85-9043, Zymed; Thermo Fisher Scientific, Inc.) (22,23). Gastric tissue specimens were obtained during surgery and fixed in 10% neutral buffered formalin for 24 h at room temperature, and were subsequently, conventionally dehydrated, embedded in paraffin and cut into 4-µm sections.…”

Section: Subjectsmentioning

confidence: 99%

Nesfatin‑1 is a potential diagnostic biomarker for gastric cancer

et al. 2019

View full text Add to dashboard Cite

The lack of reliable plasma biomarkers limits their use in the diagnosis of gastric cancer (GC). The current study aimed to determine whether plasma nesfatin-1 can be used as a novel non-invasive biomarker for the diagnosis of GC. The levels of nesfatin-1 in 40 patients with GC and 40 healthy individuals, who were selected from the Chaohu Hospital Affiliated to Anhui Medical University, were assessed. ELISA was used for the measurement of plasma nesfatin-1 levels, while immunohistochemistry was applied to determine Ki67 protein expression in GC and normal gastric tissues. The diagnostic value of plasma nesfatin-1 for GC was further assessed using receiver operating characteristic (ROC) curve analysis. The results revealed that, compared with the controls, the mean nesfatin-1 levels in patients with GC were significantly increased. Furthermore, the protein expression of Ki67 in GC tissue was significantly upregulated compared with that in normal gastric tissue. Plasma nesfatin-1 levels were also demonstrated to be correlated with Ki67 protein expression in GC tissues. Additionally, ROC curve analysis indicated the potential diagnostic value of nesfatin-1, and the area under the ROC curve (AUC) for nesfatin-1 was 0.857 (95% confidence interval, 0.769-0.946). At a threshold nesfatin-1 level of 1.075 ng/ml, the optimal sensitivity and specificity were 70.0 and 95.0%, respectively, in discriminating patients with GC from healthy controls. These results indicated that plasma nesfatin-1 may serve as a novel biomarker for the diagnosis of GC and determination of GC cell proliferation.

show abstract

The Expression of MCM7 is a Useful Biomarker in the Early Diagnostic of Gastric Cancer

Cited by 26 publications

References 33 publications

Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy

Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy

Distinct Diagnostic and Prognostic Values of Minichromosome Maintenance Gene Expression in Patients with Hepatocellular Carcinoma

Nesfatin‑1 is a potential diagnostic biomarker for gastric cancer

Contact Info

Product

Resources

About